Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Diabetes / Metabolic Women's Health Rheumatology Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Trial Radar • ClinicalTrials.gov • Registry-linked

Trial Radar

2236 clinical trials with phase, status, specialty and registry links, summarised for rapid clinical review.

2236 recruiting AI clinical summaries
Explore Trial Collections Follow research updates
All Phases Phase I Phase II Phase III Phase IV
Therapeutic Area: All Cardiology / Cardiovascular Dermatology Diabetes / Metabolic Gastroenterology Haematology Infectious Disease Men's Health Mental Health / Psychiatry Nephrology Neurology Oncology Rare Diseases
🔬
Trial Radar

Clinical Trial Intelligence

active not recruiting Phase III Oncology
A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies
Trial testing whether adding darolutamide to hormone therapy improves survival in men with early prostate cancer recurrence after surgery or radiotherapy.
19 May 2026 NCT05794906
active not recruiting Phase III Oncology
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
persevERA Trial Summary A new breast cancer drug (giredestrant) plus palbociclib compared to standard treatment (letrozole) plus palbociclib in advanced hormone-receptor-positive breast cancer.
19 May 2026 NCT04546009
● Recruiting Phase III Rheumatology
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn’s Disease or Ulcerative Colitis (MK-7240-011)
What is being tested: Long-term safety and efficacy of tulisokibart (MK-7240), a novel therapeutic agent designed to treat active, moderate to severe Crohn's disease…
19 May 2026 NCT06651281
● Recruiting Phase III Respiratory / COPD / Asthma
A Study to Evaluate the Safety and Efficacy of CD388 for Prevention of Influenza
What is being tested: CD388 is a novel therapeutic agent administered as a single dose via 3 subcutaneous injections, being evaluated for its efficacy…
19 May 2026 NCT07159763
● Recruiting Phase III Oncology
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
What is being tested: Odronextamab, a novel bispecific antibody, is being evaluated for safety, tolerability, and efficacy compared to rituximab combined with chemotherapy in…
19 May 2026 NCT06091254
● Recruiting Phase III
A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease
Emicizumab prophylaxis reduces bleeding events in Type 3 von Willebrand disease compared to standard on-demand treatment.
18 May 2026 NCT06998524
● Recruiting Phase III Cardiology / Cardiovascular
A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
What is being tested: Sotagliflozin (a dual SGLT1/SGLT2 inhibitor) efficacy and safety in reducing symptoms and functional limitations in patients with symptomatic hypertrophic cardiomyopathy,…
18 May 2026 NCT06481891
● Recruiting Phase III Oncology
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
Treatment being tested: Nemtabrutinib (a Bruton's tyrosine kinase inhibitor) combined with venetoclax compared to the standard regimen of venetoclax plus rituximab in patients with…
18 May 2026 NCT05947851
active not recruiting Phase III
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
Povetacicept reduced proteinuria and slowed kidney decline in adults with IgA nephropathy compared to placebo.
15 May 2026 NCT06564142
● Recruiting Phase III
Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).
TIGER Trial Summary Surgery plus anti-VEGF injections versus anti-VEGF alone for bleeding under the macula in wet age-related macular degeneration.
15 May 2026 NCT04663750
● Recruiting Phase III
An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia
Trial testing sodium zirconium cyclosilicate to treat high potassium levels in children aged under 18 years across correction, maintenance and long-term phases.
15 May 2026 NCT03813407
active not recruiting Phase III
HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)
Gene therapy NTLA-2002 reduced hereditary angioedema attacks more effectively than placebo in a Phase 3 trial.
15 May 2026 NCT06634420
active not recruiting Phase III
Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)
ZENITH High Proteinuria Trial Summary Adding zibotentan to dapagliflozin versus dapagliflozin alone for reducing protein loss in chronic kidney disease patients.
15 May 2026 NCT06087835
● Recruiting Phase III Cardiology / Cardiovascular
Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia
What is being tested: Inclisiran, a small interfering RNA (siRNA) therapeutic that lowers LDL cholesterol by inhibiting PCSK9 production, is being evaluated for safety,…
15 May 2026 NCT06597019
● Recruiting Phase III Oncology
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
What is being tested: Ifinatamab deruxtecan (I-DXd/MK-2400), a novel targeted therapy designed to treat metastatic castration-resistant prostate cancer (mCRPC), with the primary objective of…
15 May 2026 NCT06925737
active not recruiting Phase III
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
Satralizumab injection tested for treating thyroid eye disease by blocking inflammation.
14 May 2026 NCT06106828
● Recruiting Phase III
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder
Trial testing whether brenipatide reduces alcohol use better than placebo in people with moderate-to-severe alcohol use disorder over 56 weeks.
14 May 2026 NCT07219966
active not recruiting Phase III Oncology
DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
Tovorafenib compared to standard chemotherapy for treating children with low-grade brain tumours with RAF mutations.
14 May 2026 NCT05566795
● Recruiting Phase III Oncology
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
What is being tested: Dato-DXd (a novel antibody-drug conjugate) as monotherapy or combined with osimertinib versus standard platinum-based chemotherapy, with primary endpoint of progression-free…
14 May 2026 NCT06417814
● Recruiting Phase III Oncology
A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.
What is being tested: The addition of adjuvant (post-operative) durvalumab (PD-L1 inhibitor) versus observation alone, following neoadjuvant durvalumab plus chemotherapy and surgical resection in…
14 May 2026 NCT06284317
● Recruiting Phase III Oncology
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
What is being tested: Intravenous etentamig monotherapy is being evaluated against standard available therapies in adults with relapsed or refractory multiple myeloma to assess…
14 May 2026 NCT06158841
● Recruiting Phase III Oncology
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
Intervention being tested: Iptacopan, a complement factor B inhibitor, is being evaluated as an add-on therapy to standard of care in patients with generalized…
14 May 2026 NCT06517758
active not recruiting Phase III
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
Trial comparing two doses of ritlecitinib (50mg vs 100mg daily) for treating severe alopecia areata in people aged 12+.
13 May 2026 NCT06873945
active not recruiting Phase III Oncology
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)
T-DXd compared to T-DM1 for HER2-positive breast cancer with residual disease after chemotherapy.
13 May 2026 NCT04622319
active not recruiting Phase III Oncology
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
Venetoclax extension study collecting long-term safety data in patients continuing to benefit from treatment.
13 May 2026 NCT03844048
● Recruiting Phase III Gastroenterology
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein
Treatment being tested: Fazirsiran, an investigational therapy designed to reduce liver fibrosis in patients with alpha-1 antitrypsin (AAT) deficiency-related liver disease, compared against placebo.…
13 May 2026 NCT05677971
● Recruiting Phase III Cardiology / Cardiovascular
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
What is being tested: The efficacy of triple therapy (budesonide/glycopyrronium/formoterol – BGF MDI) versus dual therapy (glycopyrronium/formoterol – GFF MDI) in reducing cardiopulmonary outcomes…
13 May 2026 NCT06283966
● Recruiting Phase III Oncology
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
What is being tested: Datopotamab deruxtecan (Dato-DXd), a novel antibody-drug conjugate, combined with the PD-L1 inhibitor pembrolizumab versus pembrolizumab monotherapy as first-line treatment for…
13 May 2026 NCT05215340
● Recruiting Phase III
Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency
New oral medication tested in children with growth hormone deficiency to see if it works and identify who benefits most.
12 May 2026 NCT06948214
active not recruiting Phase III Oncology
A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer
T-DXd improves outcomes in HER2-positive advanced breast cancer patients previously treated with anti-HER2 drugs, including those with brain metastases.
12 May 2026 NCT04739761
● Recruiting Phase III
A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
A drug called lebrikizumab was tested for 18 months to see if it helps patients with nasal polyps who already use nasal steroid sprays.
12 May 2026 NCT06338995
● Recruiting Phase III Oncology
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
Treatment being tested: Rilvegostomig (a FGFR4 inhibitor) combined with bevacizumab, evaluated with or without tremelimumab (CTLA-4 inhibitor), compared to the current standard atezolizumab plus…
12 May 2026 NCT06921785
active not recruiting Phase II / Phase III Gastroenterology
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn’s Disease
Guselkumab, a new antibody treatment, shows promise for reducing symptoms and inflammation in moderate-to-severe Crohn's disease.
08 May 2026 NCT03466411
active not recruiting Phase III Cardiology / Cardiovascular
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
Milvexian tested against apixaban for preventing stroke and blood clots in atrial fibrillation patients.
08 May 2026 NCT05757869
● Recruiting Phase III
A Study to Investigate Efficacy and Safety of Pegtibatinase Compared With Placebo in Participants ≥12 to ≤65 Years of Age With Classical Homocystinuria (HCU) Due to Cystathionine Beta Synthase Deficiency Receiving Standard of Care Treatment
Pegtibatinase versus placebo for homocystinuria in patients aged 12-65 on standard treatment, measuring safety and effectiveness over 24 weeks.
08 May 2026 NCT06247085
active not recruiting Phase III Rheumatology
A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
Bimekizumab long-term safety and effectiveness study in ankylosing spondylitis and related spine conditions.
08 May 2026 NCT04436640
active not recruiting Phase III Rare Diseases
Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene
Gene therapy injection into the eye shows promise for treating inherited blindness caused by RPGR gene faults in men.
08 May 2026 NCT04794101
active not recruiting Phase II / Phase III Gastroenterology
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
Guselkumab was tested for treating moderate to severe ulcerative colitis, assessing whether it works and is safe.
08 May 2026 NCT04033445
● Recruiting Phase III Oncology
A Long-term Extension Study of PCI-32765 (Ibrutinib)
What is being tested: Long-term safety and efficacy of ibrutinib (PCI-32765), a Bruton's tyrosine kinase (BTK) inhibitor, in patients who have completed primary ibrutinib…
08 May 2026 NCT01804686
● Recruiting Phase III Oncology
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
Treatment being tested: Camizestrant (a selective estrogen receptor degrader) versus standard endocrine therapy in ER+/HER2- early breast cancer patients who have completed at least…
08 May 2026 NCT05774951
● Recruiting Phase III Rheumatology
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
What is being tested: Risankizumab pharmacokinetics (how the drug moves through the body), safety, and efficacy in paediatric patients with ulcerative colitis, extending evidence…
08 May 2026 NCT07071519
● Recruiting Phase III Oncology
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
What is being tested: A triple combination therapy of bleximenib plus venetoclax and azacitidine (VEN+AZA) compared to placebo with VEN+AZA alone in newly diagnosed…
08 May 2026 NCT06852222
active not recruiting Phase III Oncology
Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
New drug sacituzumab govitecan compared to standard chemotherapy docetaxel for advanced lung cancer.
07 May 2026 NCT05089734
active not recruiting Phase II / Phase III Oncology
IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients
Study testing whether radioactive iodine treatment is needed after surgery for low-risk thyroid cancer patients.
07 May 2026 NCT01398085
● Recruiting Phase III
Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant IR Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency
Trial testing oral deucrictibant tablets to prevent and treat angioedema attacks in adults with C1 inhibitor deficiency.
07 May 2026 NCT07266805
● Recruiting Phase III
Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
Long-term study showing a daily tablet (deucrictibant) safely prevents angioedema attacks in teenagers and adults with hereditary angioedema.
07 May 2026 NCT06679881
active not recruiting Phase III Oncology
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
Enzalutamide plus leuprolide safely improved outcomes in high-risk prostate cancer patients who progressed after surgery or radiotherapy.
07 May 2026 NCT02319837
active not recruiting Phase III Cardiology / Cardiovascular
Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD
Pelacarsen reduced heart attacks and strokes in patients with heart disease and high lipoprotein(a) levels.
06 May 2026 NCT04023552
● Recruiting Phase III Rheumatology
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
Anifrolumab (an interferon blocker) tested for safety and effectiveness in children with moderate to severe lupus.
06 May 2026 NCT05835310
active not recruiting Phase III
A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
Bimekizumab safety study in patients with moderate to severe hidradenitis suppurativa over long-term treatment.
06 May 2026 NCT04901195